Methylphenobarbital

Methylphenobarbital
Clinical data
Trade namesMebaral, generics
AHFS/Drugs.comInternational Drug Names
MedlinePlusa605022
Routes of
administration
By mouth (tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding70–76%
MetabolismLiver
Elimination half-life34 hours
Identifiers
  • 5-Phenyl-5-ethyl-1-methylbarbituric acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.003.714 Edit this at Wikidata
Chemical and physical data
FormulaC13H14N2O3
Molar mass246.266 g·mol−1
3D model (JSmol)
  • O=C1N(C(=O)NC(=O)C1(c2ccccc2)CC)C
  • InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18) checkY
  • Key:ALARQZQTBTVLJV-UHFFFAOYSA-N checkY
  (verify)

Methylphenobarbital (INN), also known as mephobarbital (USAN, JAN) and mephobarbitone (BAN), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant,[2] but also as a sedative and anxiolytic. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability.

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Shorvon SD, Fish DR, Perucca E, Dodson WE, eds. (2004). The Treatment of Epilepsy (2nd ed.). Blackwell. ISBN 0-632-06046-8.